… Conclusion In patients with nonvalvular atrial fibrillation or … [56] In routine practice, efforts
should be made to establish a … regarding extrapolations of comparative effectiveness. However, …

… Current practice guidelines recommend a vitamin-K antagonist (… apixaban may be a reasonable
alternative to VKA in patients … from 92 hospitals performing TAVI procedures in Germany …

… compared relative efficacy and safety of edoxaban vs. other … , and apixaban compared
with vitamin K antagonists. The … to learn about the current use of NOACs in routine practice. …

… However, despite these statements, our results also showed that clinicians still prefer
warfarin over DOAC for AF patients with BPHV in real-world practice; approximately 80% of …

… trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident
atrial fibrillation … The primary efficacy outcome was a composite of adverse events consisting of …

… vitamin K antagonists (VKA) in randomized controlled trials. However, these trial results
might not translate into routine practice… Additionally, apixaban was superior regarding risk of …

… comparing uninterrupted anticoagulation strategies, however, led to substantial heterogeneity
in clinical practice. … were seen in 27% of apixaban-treated patients vs 25% of those who …

… strategy demonstrates similar safety profile compared with … This is particularly relevant in
current clinical practice given … apixaban compared with minimally-interrupted apixaban (1 …

… therapy using apixaban is a safe alternative to vitamin K antagonist (VKA) therapy for patients
… in clinical practice and the paucity of randomized data comparing uninterrupted NOAC vs. …

… on patient characteristics, apixaban pricing, … cost effectiveness of apixaban versus
other NOACs from the perspective of the UK NHS. The authors found that apixaban is a cost-effective …